Accepted for Publication: August 24, 2021.
Published Online: September 23, 2021. doi:10.1001/jamaneurol.2021.3609
Corresponding Author: Claudio Gobbi, MD, Multiple Sclerosis Center, Department of Neurology, Neurocenter of Southern Switzerland (NSI), Ospedale Civico, Via Tesserete 46, 6900 Lugano, Switzerland (firstname.lastname@example.org).
Author Contributions: Drs Disanto and Gobbi had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Gobbi and Zecca contributed equally to the manuscript.
Concept and design: Disanto, Gobbi, Zecca.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Disanto, Gobbi.
Critical revision of the manuscript for important intellectual content: Sacco, Bernasconi, Martinetti, Keller, Gobbi, Zecca.
Statistical analysis: Disanto.
Administrative, technical, or material support: Disanto, Sacco, Zecca.
Supervision: Gobbi, Zecca.
Conflict of Interest Disclosures: Dr Bernasconi received fees for his participation on advisory boards and travel grants from Gilead Sciences, MSD, ViiV Healthcare, AbbVie, and Pfizer. Dr Gobbi received research grants or honoraria for speaking and consulting fees from Almirall, Biogen, Celgene, Merck, Novartis, Roche, Sanofi Genzyme, Teva Pharma. Dr Zecca received research grants or honoraria for speaking and consulting fees from Almirall, Biogen, Celgene, Lilly, Lundbeck, Merck, Novartis, Roche, Sanofi, Teva Pharma. No other disclosures were reported.
Funding/Support: This study was supported by institutional funds of the Neurocenter of Southern Switzerland.
Role of the Funder/Sponsor: The Neurocenter of Southern Switzerland had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
A , Mandel
M , Dreyer-Alster
et al. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord
. 2021;14:17562864211012835. doi:10.1177/17562864211012835PubMedGoogle Scholar
GN , Lao
KM , Krishnan
et al. Longitudinal characterization of the IgM and IgG humoral response in symptomatic COVID-19 patients using the Abbott Architect. J Clin Virol
. 2020;133:104663. doi:10.1016/j.jcv.2020.104663PubMedGoogle Scholar